- 1 Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium a prospective cross-
- 2 sectional nationwide study of residual samples
- 3 Herzog Sereina, PhD ^{1 *}, De Bie Jessie, PhD ^{2, 3 *}, Abrams Steven, Prof ^{3, 4}, Wouters Ine, PhD ², Ekinci
- 4 Esra, MSc², Patteet Lisbeth, PhD⁵, Coppens Astrid, MSc⁵, De Spiegeleer Sandy, MSc⁶, Beutels
- 5 Philippe, Prof¹, Van Damme Pierre, Prof², Hens Niel, Prof^{1,4}, Theeten Heidi, Prof²
- 6 ¹ Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine
- 7 & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Wilrijk, Belgium.
- 8 ² Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of
- 9 Antwerp, B-2610 Wilrijk, Belgium
- ³ Global Health Institute, Department of Epidemiology and Social Medicine, University of Antwerp, B-
- 11 2610 Wilrijk, Belgium.
- ⁴ Data Science Institute, I-BioStat, UHasselt, B-3500 Hasselt, Belgium.
- 13 ⁵ Algemeen Medisch Laboratorium (AML), Sonic Healthcare, B-2020 Antwerp, Belgium.
- 14 ⁶ Laboratoire Luc OLIVIER, B-5380 Fernelmont, Belgium.
- * Herzog Sereina and De Bie Jessie contributed equally to this paper
- 18 Corresponding author:

- 19 Sereina Herzog, Centre for Health Economics Research and Modelling of Infectious Diseases
- 20 (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp,
- 21 Universiteitsplein, 1 B-2610 Wilrijk, Belgium; herzog.sereina@gmail.com

Research in context

Evidence before this study

From 11 March to 6 July, updates on the COVID-19 pandemic by the World Health Organisation as well as bulletins from the Belgian Scientific Institute for Public Health, Sciensano, were consulted daily. Press releases and research reports from all over the world were monitored. Google, PubMed, *medrxiv, bioRxiv* were consulted for peer-reviewed articles and preprints by searching the terms "seroprevalence SARS-CoV-2" and "COVID-19". We identified an increasing number of serosurveys during the course of this study, the majority of which as yet unpublished in peer-reviewed journals. Only one nationwide peer-reviewed serosurvey was published on July 6, indicating a seroprevalence of 5.0% in Spain in the period of 27 April – 11 May 2020 (n=61075). Other peer-reviewed studies assessed seroprevalences in specific subgroups of the population (cities). More large-scale, nationwide studies are needed to assess the proportion of the population that has recently been in contact with the virus, which helps to understand the likelihood of asymptomatic infections or infections with mild symptoms.

Added value of this study

This study presents nationwide seropositivity in the Belgian population using serial serological survey data from five collection periods (March 30th - July 5th 2020) allowing to monitor acquisition of infections over three months time. The study period covers a lock-down mitigating the start of the epidemic as well as a period of release in a densely populated European country (374 persons/km²). Initial weighted overall seroprevalence was higher than expected from reported cases, and increasing quickly from 2·9% (95% CI 2·3 to 3·6) to 6·0% (95% CI 5·1 to 7·1) over 3 weeks during lockdown (from 1st to 2nd collection). The associated seroincidence was estimated at 3·1% (95% CI 1·9 to 4·3). The seroprevalence stabilized at 6·9% (95% CI 5·9-8·0) in the third collection period, and subsequently tended to decline to 5·5% (95% CI 4·7-6·5) and 4·5% (95% CI 3·7-5·4). A decrease is observed comparing the 3rd and 5th period with a seroincidence of -2·4% (95% CI -1·0 to -3·7) suggesting fast waning of IgG antibodies. Also age- and sex-specific analyses were conducted.

Implications of all the available evidence

Seroprevalence studies around the world indicate that up to July 2020 a minor fraction of the population has been exposed to SARS-CoV-2 (e.g. in Spain 5% in May). As antibody titers after mild infection seem to wane rapidly, seroprevalence estimates might only indicate exposure in the previous 2-3 months. Nevertheless, periodic monitoring of seroprevalence is valuable to understand age and location specific rapid rises in the force of infection, to control the epidemic, and to avoid a deconfinement strategy leading to large future waves. The significance of detecting SARS-CoV-2 humoral immune responses, irrespective of cellular immune responses, is currently unknown. However, if seropositivity correlates to some extent with immunity the low peak levels of seropositivity observed during this study and their rapid decline suggest that mass vaccination programmes are essential to build up sufficient population immunity.

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

Abstract Background In the first weeks of the COVID-19 epidemic in Belgium, a repetitive national serum collection was set up to monitor exposure through SARS-CoV-2 antibody detection. Main objectives were to assess the evolving age-, sex and region specific seroprevalence and seroincidence under the influence of a national lock-down, which started on 17th March. Methods This prospective serial cross-sectional nationwide seroprevalence study, stratified by age, sex and region, contains 3000-4000 samples in each of its five collection periods (March 30th – July 5th 2020). In residual sera taken outside hospitals and collected by diagnostic laboratories, IgG antibodies against S1 proteins of SARS-CoV-2 were measured with a semi-quantitative commercial ELISA. Seropositivity (cumulative, by age category and sex) and seroincidence over 3 to 4 week periods were estimated for the Belgian population. Findings The weighted overall seroprevalence initially increased from 2.9% (95% CI 2.3 to 3.6) to 6.0% (95% CI 5.1 to 7.1), implying a seroincidence of 3.1% (95% CI 1.9 to 4.3) between the 1st and 2nd collection period. Thereafter, seroprevalence stabilized and decreased from the 3rd to 5th period from 6.9% (95% CI 5.9 to 8.0) to 4.5% (95% CI 3.7 to 5.4). Interpretation During lockdown, a small but increasing fraction of the Belgian population showed serologically detectable signs of exposure to SARS-CoV-2. The decrease observed afterwards most probably reflects rapid waning of IgG antibodies.

Funding Antwerp University Fund, the Flemish Research Fund, and European Horizon 2020.

Introduction

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

The World Health Organization (WHO) announced on 11 March 2020, that the SARS-CoV2 outbreak that started in December 2019 became a pandemic. Clinical symptoms caused by the virus include loss of taste and smell, fever, malaise, dry cough, shortness of breath, and respiratory distress. Reported illnesses have ranged from very mild to severe (from progressive respiratory failure to death). In addition, increasing age, male sex, smoking, and comorbidities such as cardiovascular diseases and diabetes have been identified as risk factors for developing severe illness.³ By mid July 2020, over 12 million confirmed cases in 216 countries were reported to be infected by SARS-CoV-2 causing coronavirus disease 2019 (COVID-19).4 Currently, there is no vaccine or effective cure available to protect against or treat COVID-19. Therefore, unprecedented measures such as physical distancing, large-scale isolation and closure of borders, schools and workplaces were considered in many countries to mitigate the spread of the disease and to reduce the corresponding pressure on the respective healthcare systems. In Belgium, the first confirmed case was reported on 4 February 2020, an asymptomatic person repatriated from Wuhan.⁵ The first locally transmitted cases were confirmed on 2 March 2020. Thereafter, the number of confirmed COVID-19 cases rapidly increased. The Belgian Scientific Institute for Public Health, Sciensano, reported that as of 9 July 2020, 62210 cases were confirmed (0.5% of the Belgian population; 6.6% of the tested individuals) and 9778 died. The majority of the reported Belgian cases are in the age category of 80-89 years (19.0%; 11805/62210). Knowledge on and quantification of the age-specific susceptibility to SARS-CoV-2, and its evolution over time, related to control measures that have been taken, is tremendously important to guide policy makers aiming to control the epidemic wave and potential future waves as a result of an insufficient herd immunity level in the population. These needs were translated into the following research objectives: (1) to constitute a national serum bank on a periodic basis (cross-sectional study design) in order to estimate the seroprevalence and seroincidence in Belgium and to follow-up trends herein over time and (2) to estimate the age-specific prevalence of SARS-CoV-2 antibodies in order to identify age groups that have been infected versus those that are still susceptible as a function of time. The current nationwide study presents background seropositivity (overall, by age category, sex) in the Belgian population using serial serological survey data from five collection periods (March 30th – July 5th), which covers: (a) the implementation of the lockdown during the start of the epidemic, (b) the full lockdown period (13 March – 4 May 2020), and (c) the period when confinement measures eased (4 May onwards).

Methods

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

Study design

This prospective cross-sectional nationwide seroprevalence study is conducted in individuals aged 0-101 years. In each collection period, sera were collected over one week's time. The five collection periods represent different exposure periods: (1) 30 March – 5 April 2020, mainly represents exposure before the lockdown; (2) 20 – 26 April 2020, represents exposure prior to and during the start of the lockdown; (3) 18 - 25 May 2020, represents exposure in full lockdown; (4) 8 - 13 June 2020, represents exposure during period of first relaxation of confinement measures (re-opening of shops); and (5) 29 June – 4 July 2020, represents changes during further relaxations (partial school re-opening, opening of restaurants). A serum bank covering all Belgian regions was constituted by collecting residual sera from ten private diagnostic laboratories in Belgium. Large laboratories were engaged, with high daily throughput covering primary care and all kinds of ambulatory specialist care outside hospital. To avoid overrepresentation of subjects with acute and/or severe illness, samples collected in hospitals were excluded. Each laboratory was allocated a fixed number of samples per age group (defined in 10-year age bands, the oldest age group with ≥90 years), per region (Wallonia, Flanders, Brussels), and per collection period. The number of samples was stratified by sex within each age group. The study protocol was approved by the Ethics Committee of the University Hospital Antwerp-University of Antwerp on March 30, 2020 (ref 20/13/158; Belgian Number B3002020000047) and agreed with inclusion without informed consent, on the condition of the samples being collected unlinked and anonymously (see appendix for study protocol).

Sample size

The sample size per periodical collection has been calculated according to: (1) previous experience with various age-specific analyses of seroprevalence data in Belgium,⁷ (2) estimates of the number of COVID-19 infected people in Belgium and (3) the estimated evolution of the epidemic curve. Based on case numbers (hospitalized cases confirmed with COVID-19), the overall prevalence of COVID-19

infection at the start of the study was estimated to be about 0·4% (42797/11460000). Based on the hypothesized overall prevalence, a total sample size of 4000 in the first collection round ensures the estimation of the overall prevalence with a margin of error of 0·2%; the precision regarding the age-specific prevalence estimates is lower due to the division of samples across the age groups. However, an increase in prevalence was expected during the study period. In total, up to 16000 sera were planned to be collected, distributed over five periodic collections, and for each data collection target numbers per age group were adapted according to feasibility, sample availability and aiming at maximizing precision and assessing the impact of a change in epidemic control policy. The actual number of samples collected per period are indicated in the result section. In collection period 1 (n=4000), the planned 400 samples per age category was not reached for the age categories 0-20 and ≥90. From collection period 2 onwards (n=3000), efforts were increased to collect samples in the youngest age categories and target numbers in 70+ were decreased to maximize overall precision.

Sample preparation and analysis

After centrifugation of blood samples, selected residual sera (minimum 0.5 mL) were kept in the fridge (4-8°C) for a maximum of 14 days and finally stored at -20°C. Serology results were obtained through a semi-quantitative test kit (EuroImmun, Luebeck, Germany), measuring IgG antibodies against S1 proteins of SARS-CoV-2 in serum (ELISA). The test was performed as previously described by Lassaunière *et al.*⁸ The Dutch Taskforce Serology has compared all available data using the EuroImmun ELISA and determined a specificity of 99·2% and sensitivity ranging from 64·5% to 87·8% in pauci-symptomatic patients and patients with severe disease, respectively, using samples from patients >14 days after onset of disease symptoms.⁹ Presence of detectable IgG antibodies indicates prior exposure to SARS-CoV-2, an infection which may be resolved or is still resolving, and possibly protection against reinfection.^{8,10}

Data management

Data collected for each sample include: unique sample code, sample date, age (in years), sex, and postal code of the place of residence. From the second collection period onwards, for each sample it

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

was recorded whether or not a COVID-19 diagnostic (PCR) test was requested at the collecting laboratories. Samples were delivered anonymously to the investigators. Triage and check for duplicates was done in the collecting laboratories before anonymization. Each collection period, data were checked for completeness (based on age, sex, and postal code). Serological results (SARS-CoV-2 antibodies) were linked to the database based on the sample code. No further data entry was required. All files were kept on a secured server at the University of Antwerp, with restricted access. Data will be stored for 20 years. Statistical analysis The serostatus of an individual was considered to be positive if the measured IgG OD values were ≥1.1, equivocal IgG values were considered negative. Descriptive analysis included mapping of sample origin as well as serostatus (crude figures) up to municipality level per collection period. For all analyses, the overall seroprevalence estimate and estimates by 10-year age bands, and sex for each collection period were derived by fitting generalized linear models (binomial outcome distribution) to the serostatus of the weighted samples for each collection period. Weighted seroprevalence estimates are stated with the asymptotic 95% CIs using the design-based standard errors. The overall seroincidence estimate and estimates by 10-year age bands, and sex between collection periods were derived by calculating the difference between the corresponding estimated seroprevalence from generalized linear models (binomial outcome distribution) fitted to the serostatus of the weighted samples including an interaction term for the collection period. Weighted seroincidence estimates are displayed with corresponding 95% CIs constructed using the multivariate delta method to quantify the variability thereabout.¹¹ We assigned for each collection period weights to the samples such that they replicate the Belgian population structure according to age, sex and provinces for 2020.¹² Weights are computed by comparing the sample and population frequencies, i.e. we used a complete cross frequency table for sex and 10-year age bands and a marginal distribution for the provinces. Weights were trimmed to a maximum value of 3 to reduce the influence of samples in under-represented strata. All analyses were done with the statistical software R (version 4.0.2) using the package survey (version 4.0).¹³

Role of the funding source

The funders had no role in study design, data collection, data analysis, data interpretation, writing or submitting of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

Results

A total of 16532 serum samples were collected over five 1 week periods in -March 30th-July 5th to measure the anti-SARS-Cov2 IgG sero-status. The regional, age, and sex distribution of these samples are shown in Table 1; deviations from the population distribution were taken into account in the estimation of the weighted seroprevalences. Figure 1 shows exemplary for the collection periods 1, 2, and 5 that the origin of the samples was nicely distributed throughout Belgium (panel A-C) and that positive samples were spread over municipalities across Belgium (panel D-F); Figure S1 (appendix) shows all collection periods. The proportion of samples that had been taken to diagnose SARS-COV2 infection was 2-3% in 1st and 2nd collection and afterwards 10-11%. At the start, the seroprevalence estimates per age category ranged between 1.4% (20-30 years) and 5.9% (0-10 years) in collection period 1. The weighted overall seroprevalence showed a significant increase between collection period 1 and 2, i.e. from 2.9% (95% CI 2.3 to 3.6) to 6.0% (95% CI 5.1 to 7.1) over a period of 3 weeks (Figure 2, panel A) which is also shown by the overall seroincidence estimate of 3.1% (95% CI 1.9 to 4.3) (Figure 2, panel D). This significant increase in seroprevalence is reflected in the age categories 20-30, 80-90, and ≥90 as indicated by the seroincidence estimates (Figure 2, panel B+E) and within each sex (Figure 2, panel C+F). Among age categories in collection period 2, the seroprevalence of the oldest category (>90 years) significantly differed from the seroprevalences in age categories 10-20, 30-40, 60-70, and 70-80 years. In comparison with period 2, the overall seroprevalence stabilized thereafter to 6.9% (95% CI 5.9-8.0), 5.5% (95% CI 4.7-6.5) and 4.5 (95% CI 3.7-5.4) as shown in Figure 2 (panel A), however, a significant decrease is observed when comparing the 3rd and 5th period with a seroincidence of -2·4% (95% CI -1.0 to -3.7). This decrease was also observed for two subgroups: age category 40-50, and females. No significant differences between males and females in seroincidence or in seroprevalence were identified in any of the periods.

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

population.¹⁵

Discussion This study reports seroprevalence and seroincidence estimates of IgG antibodies against S1 proteins of SARS-CoV-2 in Belgium based on 16532 residual sera periodically collected from 30 March – 4 July 2020. The results indicate the state of the COVID-19 epidemic in Belgium, showing that only 2.9% (95% CI 2·3-3·6) of the Belgian population had detectable antibodies against SARS-CoV-2 at the start of lockdown, which doubled to 6.0% (95% CI 5.1-7.1) three weeks later but stabilized thereafter to 6.9% (95% CI 5.9-8.0), 5.5% (95% CI 4.7-6.5) and even decreased to 4.5% (95% CI 3.7-5.4). Seropositive cases were spread over the country from the beginning. These results indicate that although Belgium was heavily affected by the COVID-19 pandemic¹⁴, at the end of the study period only about 7 in hundred people had (recently) been in contact with the virus. Because little is known about the medical history of subjects of whom residual samples are collected, any potential bias is difficult to identify and control for when estimating seroprevalences. In this study, the potential for selection bias was reduced by enrolling multiple large laboratories in Belgium that collect samples from ambulatory patients throughout Belgium visiting their doctor (mainly general practitioners) for any reason including check-up, follow-up of pathology, allergy. Samples originating from hospitals were excluded from the study to avoid disproportionate selection of subjects with acute and/or severe illness including COVID-19. The majority of analyzed samples originated from two private routine laboratories in Flanders (AML) and Wallonia (laboratorie Luc OLIVIER), each with a large geographical network. These laboratories received 8000-23000 samples weekly for a variety of purposes (biochemistry, immunochemistry, hematology, etc.). For example, among the randomly selected female samples in fertile age (15-45), 11.8% had been taken for pregnancy testing, which does not suggest overselection of pregnant females. From the total of 11000-33000 samples that were weekly received by both labs, a fraction (1/3 to 1/11) samples were randomly selected according to the stratification by age category and provinces and analyzed in this study. Residual sera have previously

been used in serosurveillance studies in numerous countries, including Belgium⁷, and can provide

valuable and representative information on immunity against infectious diseases for the general

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

Stringent containment measures were enforced in Belgium as of 13 March 2020. These included travel bans, closures of schools, shops, factories and social gatherings in an effort to contain the spread of COVID-19 and decrease its burden on public health. These intervention measures slowed down the number of COVID-19 patients that were hospitalized daily. In the first two weeks of the lockdown (up to 25 March 2020), over 500 cases were hospitalized daily, and this growth rate halved 4 weeks later.⁶ By 26 April 2020, 0.1% of the Belgian population had been hospitalized for COVID-19 (14639/11·46x10⁶) and 0·4% of the Belgian population had tested positive for SARS-CoV-2 (46134/11·46x10⁶) on a total of 345047 screened patients. The estimated seroprevalence in the week of 20-26 April 2020 (6.0%, 95% CI 5.1 to 7.1) indicates that far more people had generated antibodies against SARS-CoV-2 and thus had been in contact with the virus than what was expected from the number of COVID-19 confirmed cases reported in Belgium on 26 April 2020 (0.4%). Clearly, the reported numbers of COVID-19 confirmed cases represent an underestimation and were influenced by the testing policy as testing was initially focused on the most severe cases, presenting to hospitals. Asymptomatic and mild cases were less likely reported and at different stages of the first epidemic wave, varying proportions of symptomatic cases presented to primary care, and varying proportions of these cases were tested. By end of June, the number of daily hospital admissions in Belgium dropped below 20 and the number of confirmed COVID-19 cases stabilized at a lower level than the estimated seroprevalence in Belgium (see Table 2). The current seroprevalence study in the general population thus allows in combination with the reported confirmed COVID-19 cases, to estimate the total number of recently acquired SARS-CoV-2 infections in Belgium. From the above it is clear that determination of the extent of spread of SARS-CoV-2 is a challenge as typically symptomatic patients are more likely to be diagnosed. In contrast, mainly asymptomatic and pauci-symptomatic subjects were included in the current study suggesting an underestimation of the cumulative incidence of SARS-CoV-2 infection in the population. Moreover, the sensitivity of the serological test used depends on the time since the onset of symptoms, 8 thereby preventing a fraction of the infected subjects to test seropositive if not infected long enough or too long prior to testing. By day 14 after symptom onset, IgG against SARS-CoV-2 are detectable in serum of the majority of

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

patients.² Possibly, recent SARS-CoV-2 infected subjects may have been included in the current seroprevalence study of whom antibodies were not yet detectable in blood. SARS-CoV-2 infected subjects with mild or no symptoms of whom it is reported that they may develop low or no antibodies against SARS-CoV-2, may have been included in this study as well. ¹⁶ Moreover, recently it has been reported that IgG levels start to decrease within 2-3 months after infection with SARS-CoV-2¹⁷⁻¹⁹, potentially explaining the observed decline in the 5th collection round. As a result, both paucisymptomatic subjects as well as subjects that suffered from a SARS-CoV-2 infection more than 2-3 months ago may have been falsely seronegative, and thus also cause underestimation of the incidence of infection. Male sex has been identified as a risk factor for severe COVID-19 disease. However, SARS-CoV-2 susceptibility is similar for males and females and thus no difference in seroprevalence is to be expected based on sex. 20 Nevertheless, one could argue that symptomatology goes hand-in-hand with the initiation and extent of a humoral response. Since probably no severe symptomatic cases were included in this study, any effect of disease severity and concomitant extent in humoral response in males is not detectable. The uneven infection rate of SARS-CoV-2 hampers the comparison of seroprevalence between countries. A meta-analysis by Levesque et al.²¹ reported a seroprevalence of 14% in Gangelt (Germany, 30 March - 10 April 2020, lockdown by 22 March, 100 households). A Swiss study (Geneva, 6 April – 9 May 2020, physical distancing measures by 20 March, 1339 households) estimated an increasing seroprevalence, from 4.8% (95% CI 2 ·4-8·0, n=341) to 8·5% (5·9-11.4, n=469), to 10.9% (7.9-14.4, n=577), to 6.6% (4.3-9.4, n=604), and 10.8% (8.2-13.9, n=775) in five subsequent weeks.²² A weekly serological study in Sweden (country in 'low-scale' lockdown) showed a seroprevalence of 7.3% (n=1104) in Stockholm in the week of 27 April 2020.²³ In Spain (start lockdown 14 March 2020), a national seroprevalence of 5% (4·7-5·4, n=61075) was reported in the period from 27 April – 11 May 2020.²⁴ Other preliminary serological surveys from EU Member States and USA reported that 1.0 - 3.4% of asymptomatic adult blood donors had antibodies against SARS-CoV-2 virus in the period 20 March - 12 April 2020 (i.e. first month in lockdown in reported

countries).²⁵ In London (UK, start lockdown 23 March 2020), adjusted seroprevalence estimates increased from 1.5% (end of March), to 15.4% (18 – 24 May 2020) and remained stable at 14.9% (8 – 14 June 2020). In the rest of the UK, seroprevalences are more consistent with other reports, indicating between 6.3% and 6.9% (8 – 14 June 2020). These seroprevalence estimates, as well as the ones obtained in the current study provide a consistent picture and increasing incidence of infections across Europe in spring 2020. The plateauing of seroprevalences in this study is in accordance with findings from the UK²⁶ and Spain²⁴, and can be attributed to the waning of IgG antibodies against SARS-CoV-2¹⁷⁻¹⁹ in the absence of large new exposure since the start of the epidemic in Belgium. It implies that seroprevalence studies on SARS-CoV-2 would only be able to give information on the past 2-3 months. To which extent these recovered seronegative subjects are prone to reinfection is not known yet, as it depends, among others, on eventual T-cell dependent immunity induced by the virus.²⁷ On the other hand, if presence of the antibodies we measured would correlate to some extent with immunity, levels of seropositivity observed during this study and their rapid decline suggest that we are still far away from natural herd immunity. Based on the estimated basic reproduction number (R0 ranges from 1.4 to 3.9). 28 50 – 75 % of a population would need to have protective immunity (humoral or cellular) in order to achieve herd immunity mitigating subsequent waves of COVID-19.29 Currently, it seems likely that natural exposure during this pandemic might not soon deliver the required level of herd immunity and there will be a substantial need for mass vaccination programmes to save time and lives.³⁰

Conclusion

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

Serial seroprevalence monitoring indicates that in Belgium, a densely populated country in the center of Western Europe, SARS-COV-2 virus was introduced all over the country from start and the proportion of the population infected doubled within 3 weeks' time from 3% to 6% during the start of a lockdown to mitigate the epidemic. In line with reported confirmed cases and COVID19 deaths, seroprevalence plateaued and seroincidence decreased thereafter. However, by the end of the 3-month study period a decay of the proportion seropositives was observed corroborating recent reports of quick antibody waning after mild or asymptomatic infection.^{17–19} Serial seroprevalence monitoring is a

useful tool to estimate the proportion of the population recently infected with the SARS-CoV-2 virus, and helps to understand the extend of pauci- or asymptomatic infections. The findings were extremely valuable to calibrate the Belgian response to the epidemic's first wave and to guide policy makers to control the potential future waves. The latter is still a challenge as the low reported seroprevalences (2.9-6.9%) are far from required herd immunity levels. Moreover, more research is needed to confirm if seropositivity correlates to protective immunity against the virus.

Data sharing

The authors are willing to share original data on request.

Contributors

SH, JDB and IW interpreted study results and drafted and revised the manuscript. SH also contributed to the study design and planned and performed statistical analysis. SA contributed to the study design, planned statistical analysis, interpreted study results and revised the manuscript. EE contributed to drafting the manuscript. LP and AC contributed to the study design, sample analysis and interpreted the study results and revised the manuscript. SDS contributed to sample analysis and revised the manuscript. PB, PVD, NH and HT contributed to the study design, interpreted the study results and revised the manuscript. PVD and HT also conceived the study. NH also planned the conduct of statistical analysis. All authors had access to all of the data and take full responsibility for the integrity of the data, the accuracy of the data analysis, and the finished article. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Declaration of interest

All authors have completed the Unified Competing Interest form available at www.icmje.org/coi_disclosure.pdf and declare: support to the university from research grants from GSK Biologicals, Pfizer, SANOFI, Merck, Themis, Osivax, J&J and Abbott and grants from The Bill & Melinda Gates Foundation, PATH, Flemish Government and European Union, outside the submitted work; no financial relationships with any organizations that might have an interest in the

submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgments

This work received funding from the European Union's Horizon 2020 research and innovation program - project EpiPose (No 101003688), the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement 682540 TransMID), the Flemish Research Fund (FWO 1150017N) and from The Antwerp University Fund; which is a community of donors who contribute to research and education with their personal commitment through a donation, gift, bequest or through academic chairs.

We acknowledge the Belgian laboratories that voluntarily collected sera and data for this study: Algemeen Medisch Laboratorium (AML, Antwerpen), Laboratoire Luc OLIVIER (Fernelmont), Declerck Klinisch Laboratorium (Ardooie), Klinisch Labo RIGO (Genk), Labo Anacura/Nuytinck (Evergem), Labo Somedi (Heist-op-den-Berg), Labo LBS (Brussels), Laboratoire Bauduin (Enghien), Medisch labo Bruyland (Kortrijk), Synlab (Luik).

Figure 1. Map of Belgium at municipality level, collection period 1, 2, and 5; panel A-C: number of samples tested in each municipality, panel D-F: presence of IgG-positive (red) versus exclusively IgG-negative (green) samples in each municipality.

Figure 2. Weighted seroprevalence (A, B, C) and seroincidence (D, E, F) estimates in Belgium overall (panel A+D), by 10-year age bands (panel B+E), by sex (panel C+F).

References

- WHO. Coronavirus disease 2019 (COVID-19) Situation Report 51. www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf.
- 2 Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; **579**: 270–73. https://doi.org/10.1038/s41586-020-2012-7.
- 376 3 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.
- WHO. Coronavirus disease (COVID-19) outbreak situation.
 www.who.int/emergencies/diseases/novel-coronavirus-201 (accessed Jul 13, 2020).
- FOD. Eén gerepatrieerde landgenoot testte positief op het nieuwe coronavirus. www.infocoronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus (accessed Apr 23, 2020).
- 384 6 Sciensano. Epidemiologische situatie. https://covid-19.sciensano.be/nl/covid-19-385 epidemiologische-situatie.
- Theeten H, Hutse V, Hoppenbrouwers K, Beutels P, van Damme P. Universal hepatitis B
 vaccination in Belgium: impact on serological markers 3 and 7 years after implementation.
 Epidemiol Infect 2014; 142: 251–61. https://doi.org/10.1017/S0950268813001064.
- Lassaunière R, Frische A, Harboe ZB, et al. Evaluation of nine commercial SARS-CoV-2
 immunoassays. *medRxiv* 2020. https://doi.org/10.1101/2020.04.09.20056325.
- Taskforce serologie LCT. Rapportage Status validatie van ELISA en auto-analyzer antilichaam
 testen voor diagnostiek van SARS-CoV-2; overwegingen voor gebruik. (versie 19.05.2020).
 www.nvmm.nl/media/3519/20200519_status-en-resultaten-validatie-elisa-en-auto-analyzers versie19052020 final.pdf.
- 395 10 EUROIMMUN A. Application of EUROIMMUN tests for COVID-19 diagnostics. www.coronavirus-396 diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_B.pdf (accessed 397 Apr 29, 2020).
- 398 11 Cox C. Delta Method. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Chichester, UK: 399 John Wiley & Sons, Ltd, 2005.
- 400 12 Federal Planning Bureau. Population par province et âge, au 1er janvier. www.plan.be (accessed 401 Apr 22, 2020).
- 402 13 Lumley T. survey: analysis of complex survey samples. R package version 4.0.
- 403 14 WHO. Coronavirus disease 2019 (COVID-19) Situation Report 80. www.who.int/docs/default-404 source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_6.
- 405 15 Gidding H. Australia's national serosurveillance program. NSW Public Health Bull 2003; 14: 90.
 406 https://doi.org/10.1071/NB03027.
- 407 16 van der Heide V. Neutralizing antibody response in mild COVID-19. *Nat Rev Immunol* 2020; **20**:
 408 352. https://doi.org/10.1038/s41577-020-0325-2.
- 409 17 Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-410 CoV-2 infections. *Nat Med* 2020. https://doi.org/10.1038/s41591-020-0965-6.
- Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. *medRxiv* 2020. https://doi.org/10.1101/2020.07.09.20148429.
- 19 Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl J Med* 2020. https://doi.org/10.1056/NEJMc2025179.
- 415 20 Jin J-M, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity and 416 Mortality. *Front Public Health* 2020; **8. https://doi.org/**10.3389/fpubh.2020.00152.
- Levesque J, Maybury DW. A note on COVID-19 seroprevalence studies: a meta-analysis using hierarchical modelling. *medRxiv* 2020. https://doi.org/10.1101/2020.05.03.20089201.


- 419 22 Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 lgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet* 2020.
- 421 https://doi.org/10.1016/S0140-6736(20)31304-0.
- 422 23 Folkhälsomyndigheten. Första resultaten från pågående undersökning av antikroppar för covid-
- 423 19-virus. www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-
- resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus (accessed May 20, 2020).
- 426 24 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-
- 427 COVID): a nationwide, population-based seroepidemiological study. *The Lancet* 2020.
- 428 https://doi.org/10.1016/S0140-6736(20)31483-5.


- 429 25 ECDC. Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK ninth update.
- www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirusdisease-2019-ninth-update-23-april-2020.pdf (accessed Apr 23, 2020).
- 432 26 Public Health England. Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report.
- https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data /file/897481/Weekly COVID19 Surveillance Report w26 UPDATED.pdf.
- 435 27 Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. *Sci Immunol* 2020; **5.** https://doi.org/10.1126/sciimmunol.abd6160.
- 28 D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of COVID-19 outbreak in Italy. *Biosafety and Health* 2020; **2:** 57–59. https://doi.org/10.1016/j.bsheal.2020.03.004.
- Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J Travel Med* 2020; **27.** https://doi.org/10.1093/jtm/taaa021.
- 442 30 Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19 protective immunity. *Lancet* 2020; **395:** 1527–29. https://doi.org/10.1016/S0140-6736(20)30985-5.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.08.20125179; this version posted July 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 1. Description of the study population, collection period 1 till 5

		Collection period 1 30 Mar – 5 Apr 2020		Collection period 2 20 – 26 Apr 2020		Collection period 3 18 – 25 May 2020		Collection period 4 8 – 13 June 2020		Collection period 5 29 June – 4 July 2020	
		n	%	n	%	n	%	n	%	n	%
Number of samples		3910		3397		3242		2960		3023	
Region	Wallonia	1511	38.6	1539	45.3	1292	39.9	1100	37-2	1068	35.3
	Flanders	2195	56.1	1556	45.8	1542	47.6	1526	51.6	1621	53.6
	Brussels	204	5.2	302	8.9	408	12.6	334	11.3	334	11.0
Age in years	0-10	36	0.9	85	2.5	174	5.4	124	4.2	110	3.6
	10-20	294	7.5	442	13.0	431	13.3	375	12.7	413	13.7
	20-30	436	11.2	375	11.0	414	12.8	383	12.9	394	13.0
	30-40	461	11.8	407	12.0	424	13.1	395	13.3	396	13.1
	40-50	468	12.0	406	12.0	411	12.7	394	13.3	403	13.3
	50-60	498	12.7	430	12.7	419	12.9	393	13.3	400	13.2
	60-70	507	13.0	426	12.5	417	12.9	399	13.5	403	13.3
	70-80	506	12.9	316	9.3	236	7.3	201	6.8	204	6.7
	80-90	493	12.6	315	9.3	163	5.0	166	5.6	160	5.3
	≥90	211	5.4	195	5.7	153	4.7	130	4.4	140	4.6
Sex	male	1799	46.0	1599	47.1	1587	49.0	1425	48.1	1471	48.7
	female	2111	54.0	1798	52.9	1655	52.0	1535	51.9	1552	51.3





medRxiv preprint doi: https://doi.org/10.1101/2020.06.08.20125179; this version posted July 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 2. Number of confirmed COVID-19 cases versus weighted seroprevalence in Belgium during the different collection periods

	Collection period	Average daily	Confirmed COVID-19	Weighted	Weighted	
		hospitalized	cases*	seroprevalence	seroincidence [#]	
		cases*		(with 95% CI)	(with 95% CI)	
1	30 Mar – 5 Apr 2020	499	19691/11·46 milj = 0·2%	2.9% (2.3 to 3.4)	-	
2	20 – 26 Apr 2020	204	46134/11·46 milj = 0·4%	6·0% (5·1 to 7·1)	3·1% (1·9 to 4·3)	
3	18 – 25 May 2020	27	57342/11·46 milj = 0·5%	6.9% (5.9 to 8.0)	0.9% (-0.6 to 2.3)	
4	8 – 13 Jun 2020	23	59918/11·46 milj = 0·5%	5.5% (4.7 to 6.5)	-1·4% (-2·8 to 0·03)	
5	29 Jun – 3 Jul 2020	13	61727/11·46 milj = 0·5%	4.5% (3.7 to 5.4)	-1·0 (-2·3 to 0·3)	

^{*}reported at last day of collection period by Sciensano⁶; *in comparison with previous collection period